Abstract
The signaling mechanisms responsible for BCR/ABL-induced regulation of Mcl-1 expression in chronic myelogenous leukemia (CML) cells remain unclear. In this study, we show that BCR/ABL could upregulate sphingosine kinase-1 (SPK1) expression via multiple signal pathways, including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and Janus kinase 2 (JAK2), leading to increase cellular SPK1 activity in CML cells. Retrovirus-mediated overexpression of bcr-abl gene in NIH-3T3, Ba/F3 and HL-60 cells results in upregulation and increased cellular activity of SPK1, whereas treatment of CML cells with specific inhibitors of the BCR/ABL, PI3K, MAPK and JAK2 pathways decreases BCR/ABL-induced SPK1 expression and cellular activity. BCR/ABL also induces upregulation of Mcl-1 expression in CML cells. Inhibition of SPK1 by adenovirus-mediated transfer of small interfering RNA or N,N-dimethylsphingosine reduced expression of Mcl-1 in CML cells. Our data indicated that BCR/ABL induces SPK1 expression and increases its cellular activity, leading to upregulation of Mcl-1 in CML cells. SPK1 silencing enhances the STI571-induced apoptosis of CML cell lines. It is suggested that SPK1 may be a potential therapeutic target in CML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303–3311.
Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen C . (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24: 178–187.
Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T et al. (2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20: 95–102.
Cortez D, Stoica G, Pierce JH, Pendergast AM . (1996). The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13: 2589–2594.
Duan HF, Wu CT, Lu Y, Wang H, Liu HJ, Zhang QW et al. (2004). Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells. Exp Cell Res 298: 593–601.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561–566.
Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G et al. (2004). Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 18: 1456–1458.
Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W et al. (2005). Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106: 1808–1816.
Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA et al. 2005). Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105: 3169–3177.
Lu ZZ, Ni F, Hu ZB, Wang L, Wang H, Zhang QW et al. (2006). Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp Hematol 34: 1170–1181.
Lugo TG, Pendergast AM, Muller AJ, Witte ON . (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082.
Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. (2005). Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307: 1101–1104.
Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB . (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468–6472.
Sawyers CL . (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330–1340.
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . (2000). STAT5 activation contributes to growth and viability in BCR/ABL-transformed cells. Blood 95: 2118–2125.
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt dependent pathway. EMBO J 16: 6151–6161.
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189–218.
Wattenberg BW, Pitson SM, Raben DM . (2006). The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J Lipid Res 47: 1128–1139.
Wu W, Mosteller RD, Broek D . (2004). Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 24: 7359–7369.
Xie S, Lin H, Sun T, Arlinghaus RB . (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21: 7137–7146.
Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y . (1996). N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 35: 626–633.
Zhou P, Qian L, Kozopas KM, Craig RW . (1997). Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89: 630–643.
Acknowledgements
This work was supported by Chinese National Basic Research and Development Grants ‘973’ (nos. 2004CB518801 and 2002CB713804) and Chinese National Science Foundations.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, QF., Huang, WR., Duan, HF. et al. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26, 7904–7908 (2007). https://doi.org/10.1038/sj.onc.1210587
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210587
Keywords
This article is cited by
-
Discovery and design of dual inhibitors targeting Sphk1 and Sirt1
Journal of Molecular Modeling (2023)
-
Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options
Cell Death & Disease (2020)
-
Arginine deprivation inhibits pancreatic cancer cell migration, invasion and EMT via the down regulation of Snail, Slug, Twist, and MMP1/9
Journal of Physiology and Biochemistry (2020)
-
Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
Cell Death Discovery (2018)
-
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies
Leukemia (2016)